Table of Contents
Amgen and Illumina Enter Agreement to Develop Oncology Companion Diagnostic Test
The Californian sequencing instrumentation leader, Illumina, entered into a partnership with Amgen to develop and commercialize a multigene next generation sequencing (NGS) based companion diagnostic test for the targeted drug Vectibix in metastatic colorectal cancer. This partnership marks Illumina’s entry into the NGS personalized medicine segment.
The Analyst’s Perspective by Divyaa Ravishankar, Senior Industry Analyst, Life Science North America
Various life science tools manufacturers have entered the companion diagnostic market segment in the last two years. The Amgen-Illumina partnership will be developing one of the first NGS-based companion diagnostic assays. The partnership leverages Illumina’s market leadership in NGS research platforms. The partnership also delivers a geographic advantage in the U.S. and Europe, which leads to an easier roadmap to address regulatory challenges. Illumina’s MiSeq sequencer has lowered the cost of sequencing relative to the competition, making it a suitable platform to develop the multi-gene test. Amgen partnered with Illumina for its strong track record in the commercialization of novel personalized medicine products. Examples include a partnership with DxS in 2008 for the KRAS companion diagnostic test and a partnership with Dako in 2012 for another companion diagnostic test associated with a rare cancer treatment.
NGS enables patient tumor genetic profiling and the NGS market segment is rapidly moving toward clinical diagnostics for its advantages to detect a large number of mutations simultaneously and affordably. Resulting from this work, physicians can choose the best possible treatment option personalized to the patient. In the next few years, Illumina will reap benefits from this novel diagnostic test, which will position the company in the high growth companion diagnostic segment.
Nestlé Launches New Dermatology Subsidiary Through Complete Acquisition of Galderma
Nestlé has made another strategic move in their transition toward a more healthcare focused company, with the full acquisition of dermatology specialty company, Galderma. Nestlé will fund this transaction with the sale of 48.5 million shares of Loréal in which Nestlé gains a 50% stake in Galderma from Loréal, resulting in 100% ownership of Galderma. Galderma will be the foundation of a new subsidiary, Nestlé Skin Health S.A. The transaction is pending regulatory approval.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Frontier Pharma: Head and Neck Cancer - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation Summary Head and neck cancer (HNC) is the sixth most common malignancy worldwide, ...
Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential Summary Immunology is one of the largest therapy areas, with a total of 2,145 ...
“Medical Laboratory Testing Services reaches 12 billion tests per year. Genomic technology and China healthcare expansion driving global growth.....” Report Overview: A market that just keeps on growing. ...